West Pharmaceutical Services Inc (NYSE:WST) advanced over 5% in premarket trading Thursday after reporting fourth-quarter results that topped analyst projections, supported by robust demand for its higher-margin product lines.
The injectable drug packaging and delivery specialist posted adjusted earnings of $2.04 per share for the quarter, comfortably above the $1.84 consensus estimate. Revenue reached $805 million, exceeding expectations of $796.25 million and marking a 7.5% increase year over year. Organic growth for the quarter was 3.3%.
Performance was driven largely by the company’s High-Value Product Components segment, which recorded 20.3% growth, including 15.1% organic expansion. Strength in Westar and Envision product lines contributed significantly to the results.
“Our strong finish to 2025 was a result of the team’s relentless execution of our growth strategy,” said Eric M. Green, West’s President, Chief Executive Officer and Chair of the Board. “Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth.”
Looking ahead, West issued upbeat guidance for fiscal 2026. The company expects adjusted earnings per share in the range of $7.85 to $8.20, ahead of the $7.76 analyst consensus. Full-year 2026 net sales are projected between $3.215 billion and $3.275 billion, implying organic growth of 5% to 7%.
For the first quarter of 2026, management forecasts net sales of $770 million to $790 million and adjusted EPS of $1.65 to $1.70.
For full-year 2025, West reported net sales of $3.074 billion, up 6.3% from the prior year, with organic growth of 4.3%. Adjusted EPS for the year totaled $7.29, reflecting an 8% increase compared with 2024.